结直肠癌
微卫星不稳定性
PD-L1
医学
免疫检查点
免疫疗法
癌症研究
彭布罗利珠单抗
免疫系统
无容量
封锁
化疗
CD8型
肿瘤科
癌症
癌症免疫疗法
阿替唑单抗
免疫学
肿瘤微环境
内科学
抗原
易普利姆玛
抗体
作者
Yuxiang Chen,Chi Liu,Shaomi Zhu,Xin Liang,Qinxiu Zhang,Xiaohong Luo,Lan Yuan,Linjiang Song
标识
DOI:10.1016/j.intimp.2021.107607
摘要
Colorectal cancer (CRC) is one of the most common malignant tumours of the digestive system, and most patients are already in an advanced stage at the time of diagnosis. Moreover, current single-use immune checkpoint inhibitors (ICIs), such as programmed cell death-1 (PD-1) and programmed cell death-ligand 1 (PD-L1) inhibitors, are only effective for some advanced CRC patients with microsatellite instability-high (MSI-H), and most patients may be unable to benefit from it due to a lack of CD8+ T cells in the tumour microenvironment. Additionally, the subtype of CRC has emerged as a factor affecting treatment responses, with immunogenic subtypes carrying a better prognosis. In this review, we discuss bottlenecks encountered with the single use of PD-1/PD-L1 inhibitors and summarize the research status and mechanisms of PD-1/PD-L1 inhibitor-based immunotherapeutic amplification strategies, including chemotherapy, radiotherapy, photomediated therapy and other immunotherapies used for colorectal cancer.
科研通智能强力驱动
Strongly Powered by AbleSci AI